Which thyroid antibodies should be ordered to differentiate Graves disease from Hashimoto's thyroiditis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Thyroid Antibodies for Differentiating Graves' Disease from Hashimoto's Thyroiditis

To differentiate Graves' disease from Hashimoto's thyroiditis, order TSH receptor antibodies (TRAb), thyroid peroxidase antibodies (TPOAb), and thyroglobulin antibodies (TgAb); TRAb positivity strongly suggests Graves' disease, while dual positivity of TPOAb and TgAb with negative or low TRAb indicates Hashimoto's thyroiditis.

Antibody Testing Strategy

Primary Differentiating Antibodies

  • TRAb (TSH Receptor Antibodies) is the hallmark antibody for Graves' disease, with 83.67% positivity in Graves' patients versus only 13.64% in Hashimoto's hyperthyroidism 1
  • TPOAb and TgAb combined provide the strongest diagnostic pattern for Hashimoto's thyroiditis, with dual positivity in 86.36% of Hashimoto's cases compared to 48.98% in Graves' disease 1
  • The combination of these three antibodies (TRAb, TPOAb, TgAb) provides superior diagnostic accuracy compared to testing any single antibody 2

Specific Antibody Patterns

For Graves' Disease:

  • TRAb positivity is present in approximately 84% of cases 1
  • TPOAb is positive in 75-87% of cases 1, 3
  • TgAb is positive in 48-73% of cases 1, 3
  • Higher FT3 levels (16.13 ± 9.95) correlate with TRAb positivity 1

For Hashimoto's Thyroiditis:

  • TPOAb and TgAb dual positivity occurs in 86% of cases 1
  • TRAb is typically negative or low (positive in only 13.64%) 1
  • TPOAb alone shows 86% positivity 3
  • TgAb alone shows 58% positivity 3

Clinical Algorithm for Interpretation

When TRAb is Elevated:

  • Strongly suggests Graves' disease, particularly when combined with suppressed TSH and elevated free T3 1, 4
  • TRAb levels correlate with disease activity and can predict treatment response 4
  • Radioactive iodine uptake scan can confirm diagnosis by distinguishing Graves' from destructive thyroiditis 5

When TPOAb and TgAb are Both Positive with Low/Negative TRAb:

  • Indicates Hashimoto's thyroiditis with 86% specificity 1
  • This pattern defines thyroid autoimmunity even in euthyroid patients 4
  • Predicts higher risk of progression to hypothyroidism 4

When All Three Antibodies are Positive:

  • More likely Graves' disease if TRAb is significantly elevated (>40 IU/L) 1
  • Consider overlap syndrome or potential conversion between conditions 6, 7
  • Monitor closely as 15-20% of Graves' patients may develop Hashimoto's over time 8

Important Caveats

Measurement Limitations:

  • Blocking TSH receptor antibodies (TSBAb) may be present in Hashimoto's causing atrophic thyroiditis, but stimulating antibodies in Graves' disease can overwhelm their detection in current bioassays 9
  • This technical limitation means that blocking antibodies may be underdiagnosed in clinical practice 9

Diagnostic Model Enhancement:

  • Adding clinical variables (gender, FT3 or FT4 levels) to antibody testing improves diagnostic accuracy 2
  • A diagnostic model including FT4, TGAb, TPOAb, TRAb, and gender achieved an area under the ROC curve of 0.806 for differentiating these conditions 2
  • Including radioactive iodine uptake (2-hour and 24-hour) further improves accuracy to 0.843 2

Rare Conversion Phenomenon:

  • Approximately 15-20% of Graves' patients may convert to Hashimoto's hypothyroidism over time 8
  • Conversion from Hashimoto's to Graves' is rare but possible, occurring in patients who require frequent levothyroxine dose reductions 6, 7
  • TSAb monitoring in Hashimoto's patients, particularly those who are TSAb-positive, may help predict conversion to Graves' disease 7

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.